Phospholipases in Physiology and Pathology presents a comprehensive overview on the physiology and pathology of phospholipases. This seven-volume set considers the biochemical and molecular mechanisms of normal and abnormal cell function upon dysregulation of phospholipases in different diseases. Volumes cover signal transduction mechanisms, implications in cancer, infectious diseases, neural diseases, cardiovascular diseases and other diseases, implications in inflammation, apoptosis, gene expression and non-coding RNAs, the role of natural and synthetic compounds, and stem cell therapies, nanotechnology-based therapies, and more.Together, these volumes give researchers critical insight on the mechanistic and therapeutic aspects of phospholipases. Discusses the biochemical and molecular mechanisms of normal and abnormal cell function in different disease processes Covers a wide range of basic and translational research appropriate for scientists engaged in studying the regulation of phospholipases from interdisciplinary perspectives Features state-of-the-art chapter contributions from international leaders in the field
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Copyright - p. iii 7. Copyright - p. iii 8. Copyright - p. iii 9. Copyright - p. iii 10. Copyright - p. iii 11. Copyright - p. iii 12. Dedication - p. v 13. Dedication - p. vi 14. Dedication - p. vi 15. Dedication - p. vi 16. Dedication - p. vi 17. Dedication - p. vi 18. Dedication - p. vi 19. Contents of Other Volumes - p. xiii 20. Contents of Other Volumes - p. xi 21. Contents of Other Volumes - p. xii 22. Contents of Other Volumes - p. xxi 23. Contents of Other Volumes - p. xxi 24. Contents of Other Volumes - p. xxi 25. Contents of Other Volumes - p. xxi 26. Contributors - p. xxi 27. Contributors - p. xxiv 28. Contributors - p. xxiv 29. Contributors - p. xxvi 30. Contributors - p. xxvi 31. Contributors - p. xxvi 32. Contributors - p. xxvi 33. About the Editor - p. xxvi 34. Preface - p. xxvii 35. Section A: General aspects - p. xxviii 36. Chapter 1. Biochemical mechanisms in the regulation of phospholipases - p. 3 37. Section B: Regulation of phospholipase A2 - p. 16 38. Secretory PLA2: A perspective - p. 19 39. Chapter 3. Secreted phospholipase A2 type IIA (sPLA2-IIA) binds to the allosteric site (site 2) of integrins and activates integrins in an allosteric manner - p. 39 40. Current understanding of phospholipase A2s based on knockout/transgenic mice and human diseases - p. 57 41. Chapter 5. Phospholipase A2: An emerging biomarker in vascular diseases - p. 85 42. Snake venom phospholipases A2 and their roles in snakebite envenomings - p. 105 43. Chapter 7. Secretory phospholipase II-A (shredder enzymes) and COVID-19 - p. 125 44. Chapter 8. Secretory phospholipase 2 (sPLA2) in carcinogenesis and tumor microenvironment - p. 137 45. Chapter 9. Recent insights into the role of phospholipase A2 enzymes in modulating cancer growth and development - p. 165 46. Section C: Regulation of phospholipase C - p. 178 47. Chapter 10. The role of phosphoinositide-specific phospholipase C enzymes in normal, regenerating, and pathological liver - p. 181 48. Chapter 11. Role of phospholipase A2 in cancer - p. 197 49. Chapter 12. Phospholipase C in bacterial infections - p. 217 50. Chapter 13. Mammalian phosphatidylcholine-specific phospholipase Cs - p. 235 51. Chapter 14. Role of phospholipase A and D in cardiovascular disease - p. 247 52. Section D: Regulation of phospholipase D - p. 260 53. Chapter 15. Brown spider venom phospholipases D: From molecular biology and structural analyses to potential vaccine and serum therapy applications - p. 263 54. Chapter 16. Role of phospholipase D in abiotic stress tolerance - p. 287 55. Chapter 17. Dual role of phospholipase-D in tumor progression and chemotherapy - p. 309 56. Participation of N-acyl phosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD) in the pathophysiology of the placenta - p. 321 57. Section E: Other aspects - p. 335 58. Chapter 19. Regulation and function of neutral sphingomyelinase 2 - p. 339 59. Chapter 20. Phospholipase-mediated regulation of plant's response to nutrient deficiency - p. 375 60. Chapter 21. Use of phospholipase enzymes to reduce the environmental impact of traditional chemical processes - p. 387 61. Chapter 22. Applications of lecithin:cholesterol acyltransferases, an interesting class and potent enzymes with PLA activity - p. 397 62. Chapter 23. Application of lipases and phospholipases in bioremediation of oil-contaminated environments/habitats - p. 405 63. Secretory phospholipase A2 in snake venom and revelation from cobra venomics - p. 429 64. Section A: Implications in cancer - p. 456 65. Role of the Gα13-PI3Kγ-PLD signaling axis in stimulating NADPH oxidase-derived O2•− production by urotensin II in pulmonary artery smooth muscle cells - p. 456 66. Unfurling the contradictory influence of PLA2 and its signaling mechanisms in determining the antitumorigenic or protumorigenic fate of cells - p. 18 67. Chapter 3. Exploring phospholipase D signaling in the Warburg effect and cancer - p. 38 68. Chapter 4. An insight of molecular paradigm of phospholipase D on cervical cancer - p. 55 69. Chapter 5. Crosstalk signaling of phospholipase A2 (PLA2) in lung cancer - p. 55 70. Chapter 6. Dysregulation of phospholipase C signaling pathway in breast and colorectal cancer: Association with progression and prognosis - p. 104 71. Chapter 7. Lipoprotein-associated phospholipase A2 and coronary artery disease - p. 104 72. PLA2: Implications in neurological disorders as a prospective therapeutic target - p. 104 73. Chapter 9. Molecular mechanistic insights on modulation of signal transduction pathways of phospholipase A2 in asthma and chronic obstructive pulmonary disease - p. 104 74. Chapter 10. Signal terminator or signal initiator? The inscrutable role of lipoprotein-associated PAF-acetylhydrolase (PAF-AH) in inflammation - p. 164 75. Chapter 11. Patatin-like phospholipase domain-containing protein 3 in the crossroads of hepatic fibrosis - p. 180 76. Chapter 12. Signaling and transduction mechanism of phospholipase C and isoforms in different cell types - p. 180 77. Chapter 13. Involvement of phospholipases in Mst pathway regulation - p. 180 78. Chapter 14. Potential role of virulence signaling in bacterial phospholipase C - p. 180 79. Chapter 15. Phospholipase C Signaling via G Protein-Coupled Receptors in T cells - p. 180 80. Chapter 16. Phospholipase signaling network in cancer metastasis and chemoresistance - p. 180 81. Chapter 17. Signal transduction mechanisms in the regulation of phospholipases - p. 261 82. Section A: Mechanistic aspects - p. 262 83. Role of phospholipase A2 in cancer development and progression - p. 262 84. Involvement of phospholipase A2 in gynecological cancer - p. 262 85. Role of phospholipase A2 in prostate cancer - p. 262 86. Chapter 4. Emerging roles for phospholipase A2 superfamily and their metabolites in carcinogenesis - p. 262 87. Chapter 5. The role of phospholipase D in breast cancer - p. 262 88. Chapter 6. Signal transduction mechanisms of phospholipases and their roles in cancer signaling and progression - p. 262 89. Chapter 7. Role of phospholipase A2s in gastrointestinal cancer - p. 124 90. Chapter 8. Phospholipase A2 in oral cancer - p. 124 91. Chapter 9. Current insight into the role of phospholipase A2 in breast cancer - p. 124 92. Chapter 10. Phospholipases and their metabolites in cancer - p. 124 93. Chapter 11. Stimulation of phospholipase and their action on proliferation of cells of breast cancer - p. 124 94. Phospholipase A2 in male reproductive cancers - p. 124 95. Phospholipase A2 and hepatocellular carcinoma progression - p. 124 96. Chapter 14. Role of phospholipases in hepatocellular carcinoma - p. 124 97. Chapter 15. Role of phospholipases in breast cancer - p. 124 98. Chapter 16. Role of phospholipase in relation to cancer - p. 124 99. Chapter 17. Regulation of cancer cell survival and invasion through phospholipase D - p. 124 100. Chapter 18. Role of phospholipase A2 in cancer - p. 124 101. Chapter 19. Phospholipases in cancer progression and metastasis - p. 124 102. Chapter 20. Role of phospholipase A2 in squamous cell carcinoma and breast cancer - p. 124 103. Section B: Therapeutic aspects - p. 124 104. Chapter 21. Phospholipases in human cancers: A new therapeutic target - p. 124 105. Emerging role of phospholipase A2 superfamily in cancer and treatment using radiation - p. 124 106. Chapter 23. The role of phospholipase A2 in cancers of the lungs and breast: A new therapeutic approach - p. 124 107. Chapter 24. The emerging role of phospholipase D in cancer progression and therapeutics - p. 124 108. Chapter 25. Underpinning the role of phospholipase D as a therapeutic target in cancer - p. 374 109. Chapter 26. Structural insights and functional aspects of phospholipase A2 and phospholipase D in cancer therapy - p. 404 110. Chapter 27. Emerging roles of phospholipases and lysophosphatidic acid in ovarian tumorigenesis and their therapeutic targeting - p. 423 111. Chapter 28. Phospholipase and radiation-mediated membrane dynamics - p. 423 112. Section A: General aspects - p. 476 113. Chapter 1. Phospholipases in inflammation, gene expression, and apoptosis - p. 476 114. Section B: Implication in inflammation - p. 476 115. Chapter 2. The role of phospholipases in inflammation, gene expression, and apoptosis - p. 476 116. Chapter 3. The role and regulation of phospholipase D in infectious and inflammatory diseases - p. 476 117. Chapter 4. Cytosolic phospholipase A2 (cPLA2)-mediated oxidative and inflammatory responses in neurodegenerative diseases - p. 476 118. Chapter 5. Modulation of phospholipases by phenolic compounds: Novel targets in the management of inflammatory diseases - p. 476 119. The phospholipase A2 superfamily and its role in chronic inflammatory conditions with relation to adjuster cells - p. 476 120. The role of N-acylphosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD) and its metabolites in neuroinflammation and neurodegeneration - p. 476 121. The role of phospholipase A2 in vascular health and disease - p. 476 122. Chapter 9. Phospholipase A2 as a modulator of infection, inflammation, and immunity - p. 476 123. Inflammatory effects of phospholipase A2s present in snake venom of the genus Bothrops - p. 476 124. Lipoprotein-associated phospholipase A2: Antioxidant and inflammatory role - p. 476 125. Chapter 12. Role of phospholipases in membrane remodeling, inflammation and cancer - p. 476 126. Chapter 13. Phospholipase A2-mediated regulation of inflammation and apoptosis - p. 476 127. Section C: Implication in apoptosis - p. 476 128. Chapter 14. Role of platelet-activating factor acetylhydrolase on the inflammatory and apoptotic processes in atherosclerosis - p. 476 129. Chapter 15. Functional role of phospholipase D in apoptosis and cancer - p. 476 130. Chapter 16. Phospholipases: Insights into the potential role of cell death - p. 476 131. Chapter 17. Calcium-dependent and -independent phospholipases and apoptosis - p. 476 132. Section D: Implication in gene expression and noncoding RNAs - p. 476 133. Chapter 18. Role of noncoding RNA in phospholipases-mediated diseases - p. 476 134. Chapter 19. The genetics of phospholipase A2 induced redox signaling in neuroinflammation and neuronal diseases - p. 476 135. Chapter 20. Phospholipases as pivotal players in signal transduction during tumorigenic processes - p. 338 136. Chapter 21. Functions and gene expression alterations of phospholipase C in gametes - p. 337 137. Chapter 22. Highlighting the role of phospholipase A2 and noncoding RNA in colorectal cancer - p. 337 138. Chapter 23. Crosstalk between phospholipases and noncoding RNAs in cancer - p. 337 139. Chapter 24. Relationship between phospholipases and LncRNAs during the onset of diseases - p. 337 140. Chapter 25. Epigenetic signatures in phospholipase A2 receptor genes predict cancer initiation and therapeutic progression - p. 337 141. Section A: General aspects - p. 337 142. Chapter 1. Therapeutic mode of action of synthetic compounds and phytochemicals in the molecular mechanisms of phospholipases with respect to cancer - p. 337 143. Identification of potential inhibitor(s) against phospholipase A2 using a network pharmacology-based approach - p. 337 144. Chapter 3. Functional role and therapeutic prospects of phospholipases in infectious diseases - p. 337 145. Section B: Role of natural compounds - p. 337 146. Chapter 4. Anticancer role of natural compounds targeting phospholipase A2 - p. 337 147. Natural inhibitors of phospholipase A2: Current knowledge and therapeutic approaches - p. 337 148. Recent advances of application of Berberin on phospholipase A2 (PLA2): A novel and potent therapeutic inhibitor in targeting lung cancer - p. 337 149. Marine natural products against phospholipase A2—In pursuit of novel antiinflammatory agents - p. 337 150. Section C: Role of synthetic compounds - p. 337 151. Chapter 8. Phospholipid metabolism in cancer: Role of phospholipase D and its targeting with small-molecule inhibitors as a potential therapeutic approach for cancer - p. 337 152. Chapter 9. Therapeutic approaches of phospholipase C inhibitors in breast cancer - p. 337 153. Chapter 10. Targeting phospholipase C using synthetic inhibitors of EGFR signaling for cancer treatment - p. 337 154. Chapter 11. Phospholipase A2 inhibitors in lung cancer therapy - p. 337 155. Chapter 12. Phospholipase inhibitors as cancer therapy in hepatocellular carcinoma - p. 337 156. Chapter 13. Macro understanding of the therapeutic role of phospholipase and their metabolites in pancreatic ductal and periampullary adenocarcinoma - p. 337 157. Chapter 14. Phospholipases A2 as a therapeutic target in prostate cancer - p. 337 158. Chapter 15. Phospholipase's role in maintaining and restoring skin and hair health - p. 337 159. Chapter 16. Analyzing the interaction of synthetic inhibitors with phospholipases through in silico methods - p. 337 160. Chapter 17. Phospholipase D inhibitors for targeted cancer therapy: Potentials and limitations - p. 337 161. Chapter 18. Phospholipase C isoenzyme and its role in breast cancer: A novel therapeutic approach - p. 337 162. Candida phospholipases as potential target for natural antifungals - p. 337 163. Section A: Stem cell therapies - p. 337 164. Chapter 1. Stem cells in the management of phospholipase-mediated metabolic disorders - p. 337 165. Chapter 2. Different stem cell therapeutic approaches for congenital diseases associated with phospholipase enzymes - p. 337 166. Chapter 3. Potential of stem cell therapy in phospholipase-mediated neurodegeneration - p. 337 167. Chapter 4. Advancements in stem cell-based therapeutics in phospholipase A2-dependent colorectal cancer - p. 337 168. Chapter 5. Impact of phospholipases on stem cell proliferation, differentiation, and therapy - p. 337 169. Chapter 6. Phospholipases and stem cell physiology in proliferations, differentiations, and translational research - p. 337 170. Section B: Nanotechnology based therapies - p. 337 171. Chapter 7. Phospholipase-based nanocarriers for therapeutic applications - p. 337 172. Chapter 8. Nanotherapeutic approaches for managing phospholipase-mediated neurodegenerative and metabolic diseases - p. 337 173. Chapter 9. Rational design of phospholipase-sensitive intelligent liposomal nanocarriers for prodrug and drug delivery in cancer therapy - p. 337 174. Chapter 10. Natural product-based nanomedicinal approaches for targeting phospholipases in cancer cells - p. 337 175. Section C: Bioinformatics and system biology approach - p. 337 176. Chapter 11. Protein-protein interaction mapping of phospholipase - p. 337 177. Chapter 12. Network pharmacology-based identification of potential inhibitor(s) against phospholipase A2 - p. 337 178. Chapter 13. Role of phospholipases in chronic inflammatory diseases: A systems biology perspective - p. 337 179. Natural products-based antiinflammatory compounds and phospholipase A2: Molecular docking and molecular dynamics simulations - p. 337 180. Chapter 15. Systems biology approaches to unveiling the expression of phospholipases in various types of cancer—Transcriptomics and protein-protein interaction networks - p. 337 181. Chapter 16. Phospholipase signaling in inflammation and promiscuity of phospholipase active site ligands - p. 337 182. Chapter 17. Sensors and model-based approaches applied for phospholipase activity detection - p. 337 183. Chapter 18. Phospholipases as therapeutic targets: Systems biology and bioinformatics approaches - p. 337 184. Section A: Implication in infectious diseases - p. 337 185. Implications of phospholipase A2 in fungal diseases - p. 337 186. Chapter 2. Pathological aspects of microbial phospholipases - p. 337 187. Chapter 3. Parasite phospholipases A, signaling events, and contribution to pathogenesis - p. 337 188. Chapter 4. Phospholipases in viral infection - p. 337 189. Chapter 5. Phospholipases of malaria parasite: Role in pathogenesis and potential as drug targets - p. 337 190. Chapter 6. Phospholipases in candidiasis - p. 337 191. Section B: Implication in neural diseases - p. 337 192. Chapter 7. Role and function of cPLA2 in CNS trauma and age-associated neurodegenerative diseases - p. 337 193. Chapter 8. Phospholipase C and glutamate excitotoxicity as etiological mechanism in neurological disorders - p. 337 194. The importance of phospholipases A2 in Alzheimer's disease mechanisms, pathology, and potential therapies - p. 337 195. Neurotoxicity and myotoxicity of snake venom-derived phospholipase A2 - p. 337 196. Chapter 11. Omega-3 fatty acids and neurodegenerative diseases: Focus on Alzheimer's disease - p. 337 197. Chapter 12. Role of phospholipases in neurodegenerative disorders - p. 337 198. Section C: Implication in cardiovascular diseases - p. 337 199. Chapter 13. Phospholipase A2 in cardiovascular disease - p. 337 200. Chapter 14. Association of phospholipase C and D in cardiovascular risk prediction and progression - p. 337 201. Chapter 15. Phospholipase activities in cardiovascular disease and its role as a potential biomarker in heart failure - p. 337 202. Chapter 16. Role of phospholipase C and phospholipase D in the development of hypertension - p. 337 203. Chapter 17. Endocrine regulation of phospholipase as a therapeutic target for cardiovascular diseases - p. 337 204. Biochemical mechanism of activation of cPLA2 by ONOO− in pulmonary smooth muscle cells - p. 337 205. Section D: Implication in other diseases - p. 337 206. Chapter 19. Specific PLC pathway in oocyte activation - p. 337 207. Chapter 20. Role of phospholipase A2 in the pathophysiology of preeclampsia - p. 337 208. Chapter 21. Role of phospholipase A2 and glutamate in Alzheimer's disease - p. 337 209. Chapter 22. Clinical significance of phospholipase A2 in glaucoma - p. 337 210. Chapter 23. Phospholipase A2 as a therapeutic target for treating COVID-19 - p. 337 211. Chapter 24. Phospholipases in rheumatoid arthritis and osteoarthritis - p. 337 212. Chapter 25. Role of phospholipase in liver and kidney fibrosis - p. 337 213. Index - p. 337 214. Index - p. 337 215. Index - p. 477 216. Index - p. 482 217. Index - p. 482 218. Index - p. 482 219. Index - p. 482
Phospholipases in Physiology and Pathology presents a comprehensive overview on the physiology and pathology of phospholipases. This seven-volume set considers the biochemical and molecular mechanisms of normal and abnormal cell function upon dysregulation of phospholipases in different diseases. Volumes cover signal transduction mechanisms, implications in cancer, infectious diseases, neural diseases, cardiovascular diseases and other diseases, implications in inflammation, apoptosis, gene expression and non-coding RNAs, the role of natural and synthetic compounds, and stem cell therapies, nanotechnology-based therapies, and more.Together, these volumes give researchers critical insight on the mechanistic and therapeutic aspects of phospholipases. Discusses the biochemical and molecular mechanisms of normal and abnormal cell function in different disease processes Covers a wide range of basic and translational research appropriate for scientists engaged in studying the regulation of phospholipases from interdisciplinary perspectives Features state-of-the-art chapter contributions from international leaders in the field
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Copyright - p. iii 7. Copyright - p. iii 8. Copyright - p. iii 9. Copyright - p. iii 10. Copyright - p. iii 11. Copyright - p. iii 12. Dedication - p. v 13. Dedication - p. vi 14. Dedication - p. vi 15. Dedication - p. vi 16. Dedication - p. vi 17. Dedication - p. vi 18. Dedication - p. vi 19. Contents of Other Volumes - p. xiii 20. Contents of Other Volumes - p. xi 21. Contents of Other Volumes - p. xii 22. Contents of Other Volumes - p. xxi 23. Contents of Other Volumes - p. xxi 24. Contents of Other Volumes - p. xxi 25. Contents of Other Volumes - p. xxi 26. Contributors - p. xxi 27. Contributors - p. xxiv 28. Contributors - p. xxiv 29. Contributors - p. xxvi 30. Contributors - p. xxvi 31. Contributors - p. xxvi 32. Contributors - p. xxvi 33. About the Editor - p. xxvi 34. Preface - p. xxvii 35. Section A: General aspects - p. xxviii 36. Chapter 1. Biochemical mechanisms in the regulation of phospholipases - p. 3 37. Section B: Regulation of phospholipase A2 - p. 16 38. Secretory PLA2: A perspective - p. 19 39. Chapter 3. Secreted phospholipase A2 type IIA (sPLA2-IIA) binds to the allosteric site (site 2) of integrins and activates integrins in an allosteric manner - p. 39 40. Current understanding of phospholipase A2s based on knockout/transgenic mice and human diseases - p. 57 41. Chapter 5. Phospholipase A2: An emerging biomarker in vascular diseases - p. 85 42. Snake venom phospholipases A2 and their roles in snakebite envenomings - p. 105 43. Chapter 7. Secretory phospholipase II-A (shredder enzymes) and COVID-19 - p. 125 44. Chapter 8. Secretory phospholipase 2 (sPLA2) in carcinogenesis and tumor microenvironment - p. 137 45. Chapter 9. Recent insights into the role of phospholipase A2 enzymes in modulating cancer growth and development - p. 165 46. Section C: Regulation of phospholipase C - p. 178 47. Chapter 10. The role of phosphoinositide-specific phospholipase C enzymes in normal, regenerating, and pathological liver - p. 181 48. Chapter 11. Role of phospholipase A2 in cancer - p. 197 49. Chapter 12. Phospholipase C in bacterial infections - p. 217 50. Chapter 13. Mammalian phosphatidylcholine-specific phospholipase Cs - p. 235 51. Chapter 14. Role of phospholipase A and D in cardiovascular disease - p. 247 52. Section D: Regulation of phospholipase D - p. 260 53. Chapter 15. Brown spider venom phospholipases D: From molecular biology and structural analyses to potential vaccine and serum therapy applications - p. 263 54. Chapter 16. Role of phospholipase D in abiotic stress tolerance - p. 287 55. Chapter 17. Dual role of phospholipase-D in tumor progression and chemotherapy - p. 309 56. Participation of N-acyl phosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD) in the pathophysiology of the placenta - p. 321 57. Section E: Other aspects - p. 335 58. Chapter 19. Regulation and function of neutral sphingomyelinase 2 - p. 339 59. Chapter 20. Phospholipase-mediated regulation of plant's response to nutrient deficiency - p. 375 60. Chapter 21. Use of phospholipase enzymes to reduce the environmental impact of traditional chemical processes - p. 387 61. Chapter 22. Applications of lecithin:cholesterol acyltransferases, an interesting class and potent enzymes with PLA activity - p. 397 62. Chapter 23. Application of lipases and phospholipases in bioremediation of oil-contaminated environments/habitats - p. 405 63. Secretory phospholipase A2 in snake venom and revelation from cobra venomics - p. 429 64. Section A: Implications in cancer - p. 456 65. Role of the Gα13-PI3Kγ-PLD signaling axis in stimulating NADPH oxidase-derived O2•− production by urotensin II in pulmonary artery smooth muscle cells - p. 456 66. Unfurling the contradictory influence of PLA2 and its signaling mechanisms in determining the antitumorigenic or protumorigenic fate of cells - p. 18 67. Chapter 3. Exploring phospholipase D signaling in the Warburg effect and cancer - p. 38 68. Chapter 4. An insight of molecular paradigm of phospholipase D on cervical cancer - p. 55 69. Chapter 5. Crosstalk signaling of phospholipase A2 (PLA2) in lung cancer - p. 55 70. Chapter 6. Dysregulation of phospholipase C signaling pathway in breast and colorectal cancer: Association with progression and prognosis - p. 104 71. Chapter 7. Lipoprotein-associated phospholipase A2 and coronary artery disease - p. 104 72. PLA2: Implications in neurological disorders as a prospective therapeutic target - p. 104 73. Chapter 9. Molecular mechanistic insights on modulation of signal transduction pathways of phospholipase A2 in asthma and chronic obstructive pulmonary disease - p. 104 74. Chapter 10. Signal terminator or signal initiator? The inscrutable role of lipoprotein-associated PAF-acetylhydrolase (PAF-AH) in inflammation - p. 164 75. Chapter 11. Patatin-like phospholipase domain-containing protein 3 in the crossroads of hepatic fibrosis - p. 180 76. Chapter 12. Signaling and transduction mechanism of phospholipase C and isoforms in different cell types - p. 180 77. Chapter 13. Involvement of phospholipases in Mst pathway regulation - p. 180 78. Chapter 14. Potential role of virulence signaling in bacterial phospholipase C - p. 180 79. Chapter 15. Phospholipase C Signaling via G Protein-Coupled Receptors in T cells - p. 180 80. Chapter 16. Phospholipase signaling network in cancer metastasis and chemoresistance - p. 180 81. Chapter 17. Signal transduction mechanisms in the regulation of phospholipases - p. 261 82. Section A: Mechanistic aspects - p. 262 83. Role of phospholipase A2 in cancer development and progression - p. 262 84. Involvement of phospholipase A2 in gynecological cancer - p. 262 85. Role of phospholipase A2 in prostate cancer - p. 262 86. Chapter 4. Emerging roles for phospholipase A2 superfamily and their metabolites in carcinogenesis - p. 262 87. Chapter 5. The role of phospholipase D in breast cancer - p. 262 88. Chapter 6. Signal transduction mechanisms of phospholipases and their roles in cancer signaling and progression - p. 262 89. Chapter 7. Role of phospholipase A2s in gastrointestinal cancer - p. 124 90. Chapter 8. Phospholipase A2 in oral cancer - p. 124 91. Chapter 9. Current insight into the role of phospholipase A2 in breast cancer - p. 124 92. Chapter 10. Phospholipases and their metabolites in cancer - p. 124 93. Chapter 11. Stimulation of phospholipase and their action on proliferation of cells of breast cancer - p. 124 94. Phospholipase A2 in male reproductive cancers - p. 124 95. Phospholipase A2 and hepatocellular carcinoma progression - p. 124 96. Chapter 14. Role of phospholipases in hepatocellular carcinoma - p. 124 97. Chapter 15. Role of phospholipases in breast cancer - p. 124 98. Chapter 16. Role of phospholipase in relation to cancer - p. 124 99. Chapter 17. Regulation of cancer cell survival and invasion through phospholipase D - p. 124 100. Chapter 18. Role of phospholipase A2 in cancer - p. 124 101. Chapter 19. Phospholipases in cancer progression and metastasis - p. 124 102. Chapter 20. Role of phospholipase A2 in squamous cell carcinoma and breast cancer - p. 124 103. Section B: Therapeutic aspects - p. 124 104. Chapter 21. Phospholipases in human cancers: A new therapeutic target - p. 124 105. Emerging role of phospholipase A2 superfamily in cancer and treatment using radiation - p. 124 106. Chapter 23. The role of phospholipase A2 in cancers of the lungs and breast: A new therapeutic approach - p. 124 107. Chapter 24. The emerging role of phospholipase D in cancer progression and therapeutics - p. 124 108. Chapter 25. Underpinning the role of phospholipase D as a therapeutic target in cancer - p. 374 109. Chapter 26. Structural insights and functional aspects of phospholipase A2 and phospholipase D in cancer therapy - p. 404 110. Chapter 27. Emerging roles of phospholipases and lysophosphatidic acid in ovarian tumorigenesis and their therapeutic targeting - p. 423 111. Chapter 28. Phospholipase and radiation-mediated membrane dynamics - p. 423 112. Section A: General aspects - p. 476 113. Chapter 1. Phospholipases in inflammation, gene expression, and apoptosis - p. 476 114. Section B: Implication in inflammation - p. 476 115. Chapter 2. The role of phospholipases in inflammation, gene expression, and apoptosis - p. 476 116. Chapter 3. The role and regulation of phospholipase D in infectious and inflammatory diseases - p. 476 117. Chapter 4. Cytosolic phospholipase A2 (cPLA2)-mediated oxidative and inflammatory responses in neurodegenerative diseases - p. 476 118. Chapter 5. Modulation of phospholipases by phenolic compounds: Novel targets in the management of inflammatory diseases - p. 476 119. The phospholipase A2 superfamily and its role in chronic inflammatory conditions with relation to adjuster cells - p. 476 120. The role of N-acylphosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD) and its metabolites in neuroinflammation and neurodegeneration - p. 476 121. The role of phospholipase A2 in vascular health and disease - p. 476 122. Chapter 9. Phospholipase A2 as a modulator of infection, inflammation, and immunity - p. 476 123. Inflammatory effects of phospholipase A2s present in snake venom of the genus Bothrops - p. 476 124. Lipoprotein-associated phospholipase A2: Antioxidant and inflammatory role - p. 476 125. Chapter 12. Role of phospholipases in membrane remodeling, inflammation and cancer - p. 476 126. Chapter 13. Phospholipase A2-mediated regulation of inflammation and apoptosis - p. 476 127. Section C: Implication in apoptosis - p. 476 128. Chapter 14. Role of platelet-activating factor acetylhydrolase on the inflammatory and apoptotic processes in atherosclerosis - p. 476 129. Chapter 15. Functional role of phospholipase D in apoptosis and cancer - p. 476 130. Chapter 16. Phospholipases: Insights into the potential role of cell death - p. 476 131. Chapter 17. Calcium-dependent and -independent phospholipases and apoptosis - p. 476 132. Section D: Implication in gene expression and noncoding RNAs - p. 476 133. Chapter 18. Role of noncoding RNA in phospholipases-mediated diseases - p. 476 134. Chapter 19. The genetics of phospholipase A2 induced redox signaling in neuroinflammation and neuronal diseases - p. 476 135. Chapter 20. Phospholipases as pivotal players in signal transduction during tumorigenic processes - p. 338 136. Chapter 21. Functions and gene expression alterations of phospholipase C in gametes - p. 337 137. Chapter 22. Highlighting the role of phospholipase A2 and noncoding RNA in colorectal cancer - p. 337 138. Chapter 23. Crosstalk between phospholipases and noncoding RNAs in cancer - p. 337 139. Chapter 24. Relationship between phospholipases and LncRNAs during the onset of diseases - p. 337 140. Chapter 25. Epigenetic signatures in phospholipase A2 receptor genes predict cancer initiation and therapeutic progression - p. 337 141. Section A: General aspects - p. 337 142. Chapter 1. Therapeutic mode of action of synthetic compounds and phytochemicals in the molecular mechanisms of phospholipases with respect to cancer - p. 337 143. Identification of potential inhibitor(s) against phospholipase A2 using a network pharmacology-based approach - p. 337 144. Chapter 3. Functional role and therapeutic prospects of phospholipases in infectious diseases - p. 337 145. Section B: Role of natural compounds - p. 337 146. Chapter 4. Anticancer role of natural compounds targeting phospholipase A2 - p. 337 147. Natural inhibitors of phospholipase A2: Current knowledge and therapeutic approaches - p. 337 148. Recent advances of application of Berberin on phospholipase A2 (PLA2): A novel and potent therapeutic inhibitor in targeting lung cancer - p. 337 149. Marine natural products against phospholipase A2—In pursuit of novel antiinflammatory agents - p. 337 150. Section C: Role of synthetic compounds - p. 337 151. Chapter 8. Phospholipid metabolism in cancer: Role of phospholipase D and its targeting with small-molecule inhibitors as a potential therapeutic approach for cancer - p. 337 152. Chapter 9. Therapeutic approaches of phospholipase C inhibitors in breast cancer - p. 337 153. Chapter 10. Targeting phospholipase C using synthetic inhibitors of EGFR signaling for cancer treatment - p. 337 154. Chapter 11. Phospholipase A2 inhibitors in lung cancer therapy - p. 337 155. Chapter 12. Phospholipase inhibitors as cancer therapy in hepatocellular carcinoma - p. 337 156. Chapter 13. Macro understanding of the therapeutic role of phospholipase and their metabolites in pancreatic ductal and periampullary adenocarcinoma - p. 337 157. Chapter 14. Phospholipases A2 as a therapeutic target in prostate cancer - p. 337 158. Chapter 15. Phospholipase's role in maintaining and restoring skin and hair health - p. 337 159. Chapter 16. Analyzing the interaction of synthetic inhibitors with phospholipases through in silico methods - p. 337 160. Chapter 17. Phospholipase D inhibitors for targeted cancer therapy: Potentials and limitations - p. 337 161. Chapter 18. Phospholipase C isoenzyme and its role in breast cancer: A novel therapeutic approach - p. 337 162. Candida phospholipases as potential target for natural antifungals - p. 337 163. Section A: Stem cell therapies - p. 337 164. Chapter 1. Stem cells in the management of phospholipase-mediated metabolic disorders - p. 337 165. Chapter 2. Different stem cell therapeutic approaches for congenital diseases associated with phospholipase enzymes - p. 337 166. Chapter 3. Potential of stem cell therapy in phospholipase-mediated neurodegeneration - p. 337 167. Chapter 4. Advancements in stem cell-based therapeutics in phospholipase A2-dependent colorectal cancer - p. 337 168. Chapter 5. Impact of phospholipases on stem cell proliferation, differentiation, and therapy - p. 337 169. Chapter 6. Phospholipases and stem cell physiology in proliferations, differentiations, and translational research - p. 337 170. Section B: Nanotechnology based therapies - p. 337 171. Chapter 7. Phospholipase-based nanocarriers for therapeutic applications - p. 337 172. Chapter 8. Nanotherapeutic approaches for managing phospholipase-mediated neurodegenerative and metabolic diseases - p. 337 173. Chapter 9. Rational design of phospholipase-sensitive intelligent liposomal nanocarriers for prodrug and drug delivery in cancer therapy - p. 337 174. Chapter 10. Natural product-based nanomedicinal approaches for targeting phospholipases in cancer cells - p. 337 175. Section C: Bioinformatics and system biology approach - p. 337 176. Chapter 11. Protein-protein interaction mapping of phospholipase - p. 337 177. Chapter 12. Network pharmacology-based identification of potential inhibitor(s) against phospholipase A2 - p. 337 178. Chapter 13. Role of phospholipases in chronic inflammatory diseases: A systems biology perspective - p. 337 179. Natural products-based antiinflammatory compounds and phospholipase A2: Molecular docking and molecular dynamics simulations - p. 337 180. Chapter 15. Systems biology approaches to unveiling the expression of phospholipases in various types of cancer—Transcriptomics and protein-protein interaction networks - p. 337 181. Chapter 16. Phospholipase signaling in inflammation and promiscuity of phospholipase active site ligands - p. 337 182. Chapter 17. Sensors and model-based approaches applied for phospholipase activity detection - p. 337 183. Chapter 18. Phospholipases as therapeutic targets: Systems biology and bioinformatics approaches - p. 337 184. Section A: Implication in infectious diseases - p. 337 185. Implications of phospholipase A2 in fungal diseases - p. 337 186. Chapter 2. Pathological aspects of microbial phospholipases - p. 337 187. Chapter 3. Parasite phospholipases A, signaling events, and contribution to pathogenesis - p. 337 188. Chapter 4. Phospholipases in viral infection - p. 337 189. Chapter 5. Phospholipases of malaria parasite: Role in pathogenesis and potential as drug targets - p. 337 190. Chapter 6. Phospholipases in candidiasis - p. 337 191. Section B: Implication in neural diseases - p. 337 192. Chapter 7. Role and function of cPLA2 in CNS trauma and age-associated neurodegenerative diseases - p. 337 193. Chapter 8. Phospholipase C and glutamate excitotoxicity as etiological mechanism in neurological disorders - p. 337 194. The importance of phospholipases A2 in Alzheimer's disease mechanisms, pathology, and potential therapies - p. 337 195. Neurotoxicity and myotoxicity of snake venom-derived phospholipase A2 - p. 337 196. Chapter 11. Omega-3 fatty acids and neurodegenerative diseases: Focus on Alzheimer's disease - p. 337 197. Chapter 12. Role of phospholipases in neurodegenerative disorders - p. 337 198. Section C: Implication in cardiovascular diseases - p. 337 199. Chapter 13. Phospholipase A2 in cardiovascular disease - p. 337 200. Chapter 14. Association of phospholipase C and D in cardiovascular risk prediction and progression - p. 337 201. Chapter 15. Phospholipase activities in cardiovascular disease and its role as a potential biomarker in heart failure - p. 337 202. Chapter 16. Role of phospholipase C and phospholipase D in the development of hypertension - p. 337 203. Chapter 17. Endocrine regulation of phospholipase as a therapeutic target for cardiovascular diseases - p. 337 204. Biochemical mechanism of activation of cPLA2 by ONOO− in pulmonary smooth muscle cells - p. 337 205. Section D: Implication in other diseases - p. 337 206. Chapter 19. Specific PLC pathway in oocyte activation - p. 337 207. Chapter 20. Role of phospholipase A2 in the pathophysiology of preeclampsia - p. 337 208. Chapter 21. Role of phospholipase A2 and glutamate in Alzheimer's disease - p. 337 209. Chapter 22. Clinical significance of phospholipase A2 in glaucoma - p. 337 210. Chapter 23. Phospholipase A2 as a therapeutic target for treating COVID-19 - p. 337 211. Chapter 24. Phospholipases in rheumatoid arthritis and osteoarthritis - p. 337 212. Chapter 25. Role of phospholipase in liver and kidney fibrosis - p. 337 213. Index - p. 337 214. Index - p. 337 215. Index - p. 477 216. Index - p. 482 217. Index - p. 482 218. Index - p. 482 219. Index - p. 482
